timothy sykes logo

Stock News

RXRX Surges Ahead: Is It Time to Jump In?

Ellis HobbsAvatar
Written by Ellis Hobbs Reviewed by Jack Kellogg Fact-checked by Tim Sykes
Updated 7/21/2025, 5:04 pm ET 7/21/2025, 5:04 pm ET | 7 min 7 min read
RXRX Surges Ahead: Is It Time to Jump In? Thumbnail

Recursion Pharmaceuticals Inc. stocks have been trading up by 9.08 percent following promising research breakthroughs and AI advancements announcement.

  • With full control over REV102, Recursion Pharmaceuticals is strategically positioned to harness the potential success of this treatment option.

  • Rallybio’s shares surged by 50% as they offloaded their stake in REV102 to Recursion Pharmaceuticals, which saw its own shares climb 12%.

  • The acquisition allows Recursion to fully capitalize on the joint hypophosphatasia treatment program, creating ripples in the pharma industry.

Candlestick Chart

Live Update At 17:04:16 EST: On Monday, July 21, 2025 Recursion Pharmaceuticals Inc. stock [NASDAQ: RXRX] is trending up by 9.08%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Recursion Pharmaceuticals’ Earnings and Financial Metrics

As a trader, it’s crucial to stay adaptable and learn from every experience. Trading is not just about making quick profits; it’s a continuous learning process where each trade can teach valuable lessons. As millionaire penny stock trader and teacher Tim Sykes says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” This mindset helps traders refine their techniques and enhance their decision-making skills over time. Remember, the road to success in trading is paved with persistence, learning, and growth from past experiences.

Examining the recent chart data for Recursion Pharmaceuticals (RXRX), we can see that the stock demonstrated a commendable rise in its stock price over the past few days. On Jul 16, 2025, RXRX was trading at an open price of $5.31 and closed at $5.39. Fast forward to Jul 21, 2025, and the stock was opening at $6.11 and closing at $6.4. This increasing trend in the stock price is largely attributed to savvy strategic decisions, such as acquiring full control of the REV102 program. Intraday data shows consistent trading activity and the ability to draw in investments.

When we dive into the broader picture, the financial reports, and key ratios provide a glimpse of Recursion Pharmaceuticals’ ongoing journey. Within their financial reports, certain elements stand out. They have shown a total revenue of nearly $14.75M. Yet, there’s a weighty pressure here as the total expenses soar to $206.1M, leading to a net loss of approximately $202.5M. From the balance sheet, cash and cash equivalents are around $500M, which is a vital point of liquidity that helps stabilize their operations amidst ongoing losses.

This strategic acquisition aligns well with their financial goals. By taking full ownership of REV102, they are poised to optimize revenue streams and possibly narrow down on losses from the expenditures related to this drug. On the other side, key ratios highlight a mixture of both challenges and opportunities. While return on assets stood at a concerning -42.6%, the current ratio of 4.1 indicates strong liquidity for covering short-term obligations.

From the income statement, the primary revenue contributors appear to be aligned towards significant investments in R&D expenses, which total $129.6M. An intriguing aspect is the BVPS, or book value per share, which comes in at $2.3. This offers reassurance to investors about the intrinsic value held within the company’s assets even during turbulent times.

Recursion Pharmaceuticals’ Market Impacts

With the recent surge in stock prices, let’s analyze what fueled this spike. Central to this uptick is the announcement about Recursion taking over full responsibility for REV102 from Rallybio. This acquisition has not only positioned Recursion Pharmaceuticals to maximize potential future earnings from the drug’s eventual success but also offset costs previously tied to Rallybio’s involvement.

RXRX’s share price also mirrored this optimism, climbing nearly 12% upon news of the shift in ownership. On the other hand, the transaction served as a catalyst for Rallybio’s shares, which shot up by 50%, underlining the profound market reaction. Analysts and investors are buzzing about Recursion’s strategic foresight in acquiring these rights. Could this move ceremoniously moot-proof some of their ongoing losses? The possibilities are noteworthy.

More Breaking News

The company’s ability to obtain full control over the drug’s destiny sends strong signals to industry players and market watchers alike, suggesting that RXRX may very well be on the brink of fresh financial fortunes. This development aligns with the pharma boom narrative, as Recursion Pharmaceuticals continues to leverage science and strategic partnerships to swell its pipeline.

Recursion Pharmaceuticals and Industry Trends

The pharmaceutical industry continues to ride the wave of innovation, with artificial intelligence (AI) playing an ever-more pivotal role. Another compelling facet connected to Recursion’s momentum is its partnership with MIT to harness the cutting-edge AI model, ‘Boltz-2’. Set on revolutionizing drug discovery, the AI aims to better predict molecular interactions – a vital piece of the complex drug production puzzle. This partnership, combined with the acquisition of REV102 rights, emphasizes the company’s commitment to advancing pharmaceutical technologies.

Simultaneously, Recursion seems to have taken a leaf from agile manufacturing practices. By optimizing drug design and production processes through AI, they’re positioning themselves ahead in the race to discover new treatments. Their recent moves are indicative of a company striving to accelerate time-to-market for life-saving solutions.

A vivid recollection might be visiting a bustling lab or witnessing a scientist experimenting with a complex compound. Here, hands blend chemicals, intrigue mimics curiosity, and intellectual pursuit feels palpable. Recursion Pharmaceuticals epitomizes this almost cinematic setting, not only through its innovations but also by positioning itself to immerse investors and stakeholders in a similar technological adventure.

Concluding Thoughts

In summary, RXRX’s impressive trajectory with recent strategic movements draws on the robust potential of REV102 and partnerships like that with MIT’s AI initiatives. The accelerated R&D efforts, bolstered by both liquidity cushion and visionary leadership, paints a promising picture for the future. While there are definitely hurdles to overcome in terms of profitability, the potential for long-term trading upside cannot be easily brushed aside.

As they march forward, analysts and traders have plenty to ponder. The market seems optimistic about what lies ahead, as Recursion Pharmaceuticals challenges the norms and defies expectations. Consistency in one’s approach is vital, and as millionaire penny stock trader and teacher Tim Sykes says, “Consistency is key in trading; don’t let emotions dictate your trades.” With the right shove in terms of innovation and market opportunities, RXRX could achieve a promising rally in stock valuation. Whether you’re seasoned in pharmaceuticals or just someone eager to see how these moves shape the broader industry, Recursion Pharmaceuticals seems to have set the stage for a captivating market saga.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Ellis Hobbs

Trainer and Mentor on Tim Sykes’ Trading Challenge
He teaches webinars on Tim Sykes’ Trading Challenge He treats trading like a business, not a hobby He emphasizes taking small risks — “If you get the process right, money is a forgone conclusion.”
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”